Standard BioTools–Canaccord Genuity: investor conference, 202408 supply service Standard BioTech participates in Canaccord Genuity Growth Conference

	Period	2024-08-13
	Partner, 1st	Standard BioTools Inc. (Nasdaq: LAB)
	Group	Standard BioTools (Group)
	Partner, 2nd	Canaccord Genuity (Group)
	Product	Canaccord Genuity Annual Growth Conference 2024 Boston
	Product 2	laboratory equipment and instruments
	Person	Egholm, Michael (Fluidigm 2022Q2– CEO before Danaher Life Sciences + Pall + 454 Life Sciences + Molecular Staging)
	Person 2	Holmes, David (Gilmartin Group 202408)

Standard BioTools Inc.. (8/6/24). "Press Release: Standard BioTools to Participate in Upcoming Investor Conferences". South San Francisco, CA.

Standard BioTools Inc. (Nasdaq:LAB), today announced that its management team will participate in the following investor conferences in the month of August:

> Canaccord Genuity 44th Annual Growth Conference on August 13th, 2024
President and CEO, Michael Egholm, PhD, will participate in a fireside chat on Tuesday, August 13, 2024, at 9:00 a.m. ET

> UBS Genomic Medicine Summit on August 14th, 2024
President and CEO, Michael Egholm, PhD, will participate in a panel discussion:
Expanding Horizons - Spatial and Beyond on Wednesday, August 14, 2024, at 2:00 p.m. PT

Available presentations will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices.

Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners.

©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Investor Contact:

David Holmes
Gilmartin Group LLC
(332) 330-1031
[email protected]